Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

SAT-291 EFFECTS OF ERTUGLIFLOZIN ON UACR AND eGFR IN PATIENTS WITH TYPE 2 DIABETES (T2D) AND CKD STAGE 3

M. Maldonado,D. Cherney, R. Frederich,J. Liu,A. Pong, J. Xu,S. Terra,G. Ira

Kidney International Reports（2019）

Cited 0|Views35
No score
Abstract
Ertugliflozin is a SGLT2 inhibitor. The primary results of a clinical study evaluating the safety and efficacy of ertugliflozin over 52 weeks in patients with chronic kidney disease (CKD) were recently published. The aim of this post hoc analysis was to further describe the effect of ertugliflozin on UACR and eGFR.
More
Translated text
Key words
ertugliflozin on uacr,egfr,diabetes
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined